DYADIC INTERNATIONAL INC

DYAI
About the company

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.

Country: United StatesPrice: $0.33Market Cap: $13.1M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILPASSFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio9.7x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-75.9%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-75.9%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share9.7x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=9.7x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($0.33)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-58.18%; #5132/6340 (top 80.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-0.1822; #5800/6449 (top 89.9%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share9.69x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-96.7%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.2902; #3362/5247 (top 64.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-62.95%; #5470/6202 (top 88.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing
      ✗LynchPositive and growing
      Operating Cash Flow$-5.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-57.33%, ROA=-74.05%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/9 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag DYAI's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/10 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/10 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-221.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-232.8% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-75.9%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-75.9%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-74.05%
      ✗PiotroskiROA > 0
      ROA Change YoY-58.50% -> -74.05% (delta: -15.55%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-57.33%, ROA=-74.05%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY65.8% -> 24.9%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-237.3%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of SafetyP/B=9.7x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-316.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/9 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-195.1%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-283.9% (2023) -> -232.8% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 31.8% -> 24.9%, operating margin -283.9% -> -232.8%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-58.18%; #5132/6340 (top 80.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+7.75%; #2944/3702 (top 79.5%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0876; #3316/5884 (top 56.4%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/7 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Growth13% pass✓ 3✗ 10▾

      7 of 8 flag DYAI's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.07 (2017) -> $-0.23 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/9 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-1.1%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency0/2 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 31.8% -> 24.9%, operating margin -283.9% -> -232.8%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR14.0%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency13% pass✓ 1✗ 10▾

      7 of 8 flag DYAI's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio1.65
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY4.01 -> 2.68
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.35x -> 0.31x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities1.65
      ✓Dreman> 1.5
      Return on Invested Capital-254.5%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=-254.5%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/1 years above 12% (latest -254.5%)
      ✗SleepROIC > 12% in a majority of years
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag DYAI's debt & leverage — Graham, Buffett, Lynch +5 more

      Total Debt / Shareholders' Equity0.81
      ✗Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.81, IC: -17.4x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.81
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.65
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Debt Levels0.81
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-17.4x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.81
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.8114; #3011/4210 (top 71.5%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($13.1M)
    Revenue: $3.1M-11.6% YoY
    Net Income: $7.4M-26.8% YoY

    Financial Snapshot

    Operating Margin-232.8%
    Return on Equity-597.6%
    Debt / Equity0.81
    Current Ratio2.68
    EPS (Diluted)$-0.23
    Shares Retired−21.3% / −25.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 21.3% of shares last year, 25.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, ebit, operating cash flow.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-25
    FY 2024
    Sources
    • 10-K · 2025-03-26
    FY 2023
    Sources
    • 10-K · 2024-03-28
    FY 2022
    Sources
    • 10-K · 2023-03-29
    FY 2021
    Sources
    • 10-K · 2022-03-29
    Market Cap$13.1Mcurrent------$31.5Mest.$44.5Mest.$37.5Mest.$50.6Mest.$105.3Mest.
    Revenue$3.1M↓8%$449.1K↓61%$961.1K↓1%$1.1M↑182%$3.1M↓12%$3.5M↑21%$2.9M↓1%$2.9M↑22%$2.4M
    Operating Income-$7.3M↓2%-$1.8M↑6%-$2.1M↓19%-$1.9M↑5%-$7.2M↓22%-$5.9M↑28%-$8.2M↑19%-$10.2M↑31%-$14.7M
    Net Income-$7.0M↑5%-$1.4M↑31%-$2.1M↓18%-$2.0M↑4%-$7.4M↓27%-$5.8M↑15%-$6.8M↑30%-$9.7M↑26%-$13.1M
    EPS (Diluted)--$-0.04↑33%$-0.06$-0.05$-0.23↓15%$-0.20----$-0.47
    Gross Margin————24.9%↓62%65.8%↑107%31.8%↑16%27.5%↑44%19.1%
    Operating Margin-236.7%↓10%-403.6%↓144%-213.7%↓19%-171.3%↑66%-232.8%↓38%-168.8%↑41%-283.9%↑18%-346.9%↑43%-612.7%
    ROE271.7%↑196%———-597.6%↓154%-235.2%↓103%-115.6%↓32%-87.8%↓24%-71.1%
    Total Debt--------$1.0M--------
    Shareholders' Equity-$2.6M↓199%-$2.6M↓199%-$2.4M↓351%-$407.7K↓144%$1.2M↓50%$2.5M↓58%$5.9M↓47%$11.1M↓40%$18.4M
    Current Ratio1.69↓41%1.69↓41%1.65↓18%2.42↓39%2.68↓33%4.01↑12%3.58↓35%5.48↓33%8.22
    Debt / Equity————0.81————
    Operating Cash Flow-$7.0M↓52%-$1.5M↑20%-$1.8M↓1298%-$2.0M↓1%-$5.7M↓43%-$4.0M↑41%-$6.7M↑17%-$8.1M↑28%-$11.3M
    Free Cash Flow------------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    DYAI vs Peers — Financial Grading

    Revenue$3.1MBottom 25%
    Net Income$7.4MMedian
    ROE-597.6%Bottom 25%
    D/E0.81Median
    Op. Margin-232.8%Bottom 25%
    Curr. Ratio2.68Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11